Silence Therapeutics plc
Business
Silence Therapeutics is a biotechnology company developing siRNA therapeutics using its proprietary mRNAi GOLD platform to silence disease-associated genes, with a pipeline targeting rare hematologic and cardiometabolic diseases. The company's lead candidates include divesiran (Phase 2 for polycythemia vera), zerlasiran (Phase 3-ready for cardiovascular disease associated with elevated lipoprotein(a)), and several earlier-stage programs addressing obesity, hypercholesterolemia, and complement-mediated renal diseases. Silence operates through clinical development and partnership collaborations, with recent programs partnered with AstraZeneca (now being returned) and previously with Hansoh in China.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Revenue | 559,000 | 43 | 32 | 22 | |
| Cost of sales | −215,000 | −12 | −13 | −13 | |
| Gross profit | 344,000 | 31 | 19 | 8 | |
| Research and development costs | −68 | −68 | −57 | −44 | |
| General and administrative expenses | −22 | −27 | −26 | −26 | |
| Restructuring charges | −1 | 0 | — | — | |
| Operating loss | −91 | −63 | −64 | −61 | |
| Foreign currency (loss)/gain, net | −8 | 646,000 | −3 | 1 | |
| Other income, net | 3 | 4 | 2 | 280,000 | |
| Benefit from R&D credit | 7 | 14 | 12 | 10 | |
| Loss before income tax expense | −89 | −44 | −53 | −50 | |
| Income tax expense | −11,000 | −845,000 | −956,000 | −688,000 | |
| Net Loss | −89 | −45 | −54 | −50 | |
| Loss per share basic | −0.63 | −0.33 | −0.49 | −0.52 | |
| Loss per share diluted | −0.63 | −0.33 | −0.49 | −0.52 | |
| Weighted-average shares outstanding basic | 142 | 139 | 111 | 97 | |
| Weighted-average shares outstanding diluted | 142 | 139 | 111 | 97 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 11 | 121 | 69 | — | — | |
| Short-term investments | 74 | 26 | — | — | — | |
| R&D benefit receivable | 22 | 24 | 22 | — | — | |
| Other current assets | 12 | 15 | 12 | — | — | |
| Trade receivables | 0 | 972,000 | 290,000 | — | — | |
| Total current assets | 119 | 187 | 103 | — | — | |
| Property, plant and equipment, net | 2 | 2 | 2 | — | — | |
| Operating lease right-of-use asset | 167,000 | 157,000 | 370,000 | — | — | |
| Goodwill | 11 | 9 | 10 | 10 | — | |
| Intangible assets | 288,000 | 312,000 | — | — | — | |
| Other long-term assets | 127,000 | 4 | 4 | — | — | |
| Total assets | 131 | 203 | 119 | — | — | |
| Contract liabilities | −168,000 | −306,000 | −7 | — | — | |
| Trade and other payables | −13 | −16 | −16 | — | — | |
| Operating lease liabilities, current | −89,000 | −117,000 | −228,000 | — | — | |
| Total current liabilities | −14 | −17 | −22 | — | — | |
| Contract liabilities | −55 | −52 | −75 | — | — | |
| Operating lease liabilities, long-term | −71,000 | 0 | −118,000 | — | — | |
| Total liabilities | −69 | −69 | −97 | — | — | |
| Commitments and contingencies (Note 21) | — | — | — | — | — | |
| Ordinary shares - par value �.05 per share; 141,701,848 shares issued at December 31, 2025 (2024: 141,674,074) | −10 | −10 | −9 | −8 | — | |
| Additional paid-in capital | −618 | −610 | −456 | — | — | |
| Accumulated deficit | 563 | 474 | 432 | — | — | |
| Accumulated other comprehensive loss | 3 | 12 | 11 | — | — | |
| Total shareholders' equity | −62 | −134 | −22 | −27 | −12 | |
| Total liabilities and shareholders' equity | −131 | −203 | −119 | — | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Net loss after tax | −89 | −45 | −54 | −50 | |
| Depreciation expense | 300,000 | 300,000 | 400,000 | 400,000 | |
| Amortization expense | 243,000 | 257,000 | 252,000 | 217,000 | |
| Share-based compensation expense | 8 | 16 | 16 | 13 | |
| Net foreign exchange impacts | 11 | −3 | 4 | −1 | |
| Other income, net | −3 | −4 | −2 | −280,000 | |
| Income tax expense | 11,000 | 845,000 | 956,000 | 688,000 | |
| Decrease/(increase) in trade receivables | 1 | −904,000 | 392,000 | −723,000 | |
| Decrease/(increase) in other current assets | 6 | −1 | 2 | −5 | |
| Decrease/(increase) in R&D benefit receivable | 4 | −2 | −3 | −10 | |
| Decrease in other long-term assets | 4 | — | −3 | — | |
| (Decrease)/increase in trade and other payables | −4 | 499,000 | −473,000 | 2 | |
| Decrease in contract liabilities | −334,000 | −29 | −10 | −5 | |
| Decrease in operating lease liabilities | −168,000 | −165,000 | −175,000 | −235,000 | |
| Net cash used in operating activities | −62 | −68 | −49 | −57 | |
| Redemption of term deposits | 118 | 117 | 45 | — | |
| Purchase of term deposits | −166 | −139 | −26 | −20 | |
| Purchase of property, plant and equipment | −55,000 | −211,000 | −56,000 | −173,000 | |
| Net cash used in investing activities | −48 | −22 | 19 | −20 | |
| Proceeds from issue of ordinary shares | 15,000 | 142 | 32 | 53 | |
| Net cash provided by financing activities | 15,000 | 142 | 32 | 53 | |
| (Decrease)/increase in cash and cash equivalents | −110 | 52 | 2 | −25 | |
| Effect of exchange rate fluctuations on cash and cash equivalents held | 195,000 | 60,000 | 749,000 | −8 | |
| Income Tax Paid net of refunds | −637,000 | −433,000 | −801,000 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Silence Therapeutics plc's CIK number?
Silence Therapeutics plc's SEC CIK number is 0001479615 (1479615). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Silence Therapeutics plc's SEC filings?
All of Silence Therapeutics plc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Silence Therapeutics plc last report earnings?
Silence Therapeutics plc (SLN) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-210428). This is Silence Therapeutics plc's most recent earnings filing of record — not a forecast of its next earnings date.
What is Silence Therapeutics plc's most recent earnings 8-K?
Silence Therapeutics plc's latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-210428. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Silence Therapeutics plc's latest earnings 8-K →
Look up any company's CIK number →